PH12023550133A1 - Dendrimer compositions and methods for drug delivery to injured kidney - Google Patents
Dendrimer compositions and methods for drug delivery to injured kidneyInfo
- Publication number
- PH12023550133A1 PH12023550133A1 PH1/2023/550133A PH12023550133A PH12023550133A1 PH 12023550133 A1 PH12023550133 A1 PH 12023550133A1 PH 12023550133 A PH12023550133 A PH 12023550133A PH 12023550133 A1 PH12023550133 A1 PH 12023550133A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- dendrimer
- drug delivery
- disorder
- symptoms
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 3
- 229920000736 dendritic polymer Polymers 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000012377 drug delivery Methods 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010061481 Renal injury Diseases 0.000 abstract 2
- 208000017169 kidney disease Diseases 0.000 abstract 2
- 208000037806 kidney injury Diseases 0.000 abstract 2
- 229920000962 poly(amidoamine) Polymers 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053228P | 2020-07-17 | 2020-07-17 | |
| PCT/US2021/042097 WO2022016120A1 (en) | 2020-07-17 | 2021-07-16 | Dendrimer compositions and methods for drug delivery to injured kidney |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023550133A1 true PH12023550133A1 (en) | 2024-06-24 |
Family
ID=79555049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/550133A PH12023550133A1 (en) | 2020-07-17 | 2021-07-16 | Dendrimer compositions and methods for drug delivery to injured kidney |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230364244A1 (enExample) |
| EP (1) | EP4181913A4 (enExample) |
| JP (1) | JP2023534812A (enExample) |
| CN (1) | CN116249558A (enExample) |
| AU (1) | AU2021310470A1 (enExample) |
| CA (1) | CA3189682A1 (enExample) |
| IL (1) | IL299891A (enExample) |
| PH (1) | PH12023550133A1 (enExample) |
| WO (1) | WO2022016120A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022552818A1 (en) | 2020-04-24 | 2024-03-25 | Ashvattha Therapeutics Inc | Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome |
| EP4237009A4 (en) * | 2020-10-30 | 2025-09-24 | Ashvattha Therapeutics Inc | Radiolabeled ether dendrimer conjugates for PET imaging and radiotherapy |
| US20250333732A1 (en) * | 2022-05-23 | 2025-10-30 | Empirico Inc. | Treatment of sos2 related diseases and disorders |
| WO2025137151A2 (en) * | 2023-12-18 | 2025-06-26 | The Johns Hopkins University | Dendrimer compositions for the treatment of atherosclerosis, obesity, and metabolic syndromes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012116753A (ja) * | 2009-03-26 | 2012-06-21 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
| WO2011053618A2 (en) * | 2009-10-30 | 2011-05-05 | The Regents Of The University Of Michigan | Hydroxyl-terminated dendrimers |
| WO2016025741A1 (en) * | 2014-08-13 | 2016-02-18 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| CN105879055A (zh) * | 2014-11-11 | 2016-08-24 | 董勤 | 载cxcr4小分子rna聚酰胺树枝状聚合物纳米微粒 |
| JP7108306B2 (ja) * | 2015-10-29 | 2022-07-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用 |
| JP7088473B2 (ja) * | 2015-10-29 | 2022-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 |
| US11771702B2 (en) * | 2018-11-30 | 2023-10-03 | Amiram Goldblum | Agonists of PPAR-δ |
| AU2020397063A1 (en) * | 2019-12-04 | 2022-07-07 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
| AU2020397064A1 (en) * | 2019-12-04 | 2022-07-07 | Ashvattha Therapeutics, Inc. | Triantennary N-Acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof |
-
2021
- 2021-07-16 EP EP21841182.5A patent/EP4181913A4/en active Pending
- 2021-07-16 CN CN202180062066.1A patent/CN116249558A/zh active Pending
- 2021-07-16 IL IL299891A patent/IL299891A/en unknown
- 2021-07-16 CA CA3189682A patent/CA3189682A1/en active Pending
- 2021-07-16 US US18/016,262 patent/US20230364244A1/en active Pending
- 2021-07-16 PH PH1/2023/550133A patent/PH12023550133A1/en unknown
- 2021-07-16 WO PCT/US2021/042097 patent/WO2022016120A1/en not_active Ceased
- 2021-07-16 AU AU2021310470A patent/AU2021310470A1/en active Pending
- 2021-07-16 JP JP2023503110A patent/JP2023534812A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4181913A4 (en) | 2025-02-19 |
| US20230364244A1 (en) | 2023-11-16 |
| CA3189682A1 (en) | 2022-01-20 |
| CN116249558A (zh) | 2023-06-09 |
| JP2023534812A (ja) | 2023-08-14 |
| AU2021310470A1 (en) | 2023-03-02 |
| EP4181913A1 (en) | 2023-05-24 |
| IL299891A (en) | 2023-03-01 |
| WO2022016120A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551368A1 (en) | Dendrimer compositions and methods for drug delivery | |
| Di Francesco et al. | Management of osteoarthritis: From drug molecules to nano/micromedicines | |
| Vadivelu et al. | Article commentary: pain after mastectomy and breast reconstruction | |
| Kirshblum | Treatment alternatives for spinal cord injury related spasticity | |
| JP5513893B2 (ja) | 組織増大用インプラント | |
| BR0008847A (pt) | Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas | |
| Hasegawa et al. | Review on nerve blocks utilized for perioperative total knee arthroplasty analgesia | |
| JP2016540830A (ja) | 水性カプサイシノイド配合物ならびに製造法および使用法 | |
| WO2021243467A1 (en) | Cannabinoid-hyaluronic acid bioconjugates | |
| JP6961055B2 (ja) | ホメオパシー的療法的方法および組成物 | |
| MX2022012501A (es) | Portadores para suministro eficiente de ácido nucléico. | |
| Wu et al. | Adhesive polydopamine-based photothermal hybrid hydrogel for on-demand lidocaine delivery, effective anti-bacteria, and prolonged local long-lasting analgesia | |
| Feng et al. | Adaptive phenol-based hydrogel embedded with metformin nanoparticles targets oxidative stress and ferroptosis for spinal cord injury repair | |
| US20260115148A1 (en) | Homeopathic therapeutic method and compositions | |
| Li et al. | Dual-drug loaded hyaluronic acid conjugates coated polydopamine nanodrugs for synergistic chemo-photothermal therapy in triple negative breast cancer | |
| PH12022552818A1 (en) | Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome | |
| Ashworth | Peyronie's disease | |
| WO2023003518A2 (en) | Methods, compositions and kits for fat remodelling | |
| US20190307925A1 (en) | Polyacrylamide hydrogel for use in the prevention and/or treatment of synovitis in a mammal | |
| CN115887688A (zh) | 一种自适应的缺血性脑卒中递药系统及其制备方法和应用 | |
| Modak et al. | Pre-emptive gabapentin for postoperative pain relief in abdominal hysterectomy | |
| Taylor | Pharmacological approaches to pain management in the horse. | |
| Junior et al. | Increasing muscular volume with hyaluronic acid | |
| Gu et al. | Advanced molecularly imprinted polymers for disease treatment via targeting molecular abnormalities: Promises and challenges | |
| Chen | Photoresponsive cancer cell membrane-coated drug delivery systems for cancer treatment |